RegeneRx Biopharmaceuticals Accounts Payable

RegeneRx Biopharmaceuticals (RGRX) currently reports a accounts payable of $0 as of September 2023. That compares with $37K in the prior-year period — down 100.0% year over year. Use the charts on this page to explore RegeneRx Biopharmaceuticals's accounts payable history and peer comparisons.

RegeneRx Biopharmaceuticals's accounts payable decreased from $37K to $0 — a 100.0% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

RegeneRx Biopharmaceuticals reported $0 in accounts payable as of September 2023. That compares with $37K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for RegeneRx Biopharmaceuticals, and consider following RGRX for alerts when major investors trade the stock.

RegeneRx Biopharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RGRX with unrelated industries.